Moisture-Activated Dry Granulation Part II: The Effects of Formulation Ingredients and Manufacturing-Process Variables on Granulation Quality Attributes - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Moisture-Activated Dry Granulation Part II: The Effects of Formulation Ingredients and Manufacturing-Process Variables on Granulation Quality Attributes
In this article, the authors evaluated the effects of the granulating binder level, binder type, water amount, and water-droplet size on the MADG process.


Pharmaceutical Technology
Volume 33, Issue 12, pp. 42-51

Conclusions

The MADG is a simple, clean, lean, and robust process for particle-size enlargement. The results from the evaluation of the effects of the granulating binder level, binder type, water amount, and water-droplet size suggest that the MADG process is robust and creates granulation with good physical properties and finished products with satisfactory quality attributes. The process is applicable to most of the granulation needs for solid dosage-form development as practiced in the pharmaceutical industry. It is essentially a one-pot granulation process. It is also an economical, energy-saving, green, and efficient manufacturing process. The MADG process has advantages such as short manufacturing time and few critical formulation and process variables. These advantages make the MADG process a better candidate than conventional wet- or dry-granulation processes for QbD concepts. Because the MADG process does not require drying or milling, it is suited for use as a continuous process.

Acknowledgements

The authors are grateful to FMC BioPolymer and Evonik Degussa for providing samples of micro crystalline cellulose (Avicel PH200 Low Moisture) and silicon dioxide (Aeroperl 300), respectively.

The authors also sincerely thank their colleagues in the biopharmaceutics research and development department at BMS for their help in executing various experiments and for their constant support and encouragement. In particular, we appreciate Maurice Lobo's and Jeffrey Hemenway's thoughtful comments and tablet-content uniformity data of various compounds.

Ismat Ullah is president of Simple Pharma Solutions (Cranbury, NJ). Jennifer Wang* is a senior research investigator, Shih-Ying Chang is a principal scientist, Hang Guo is a research scientist, San Kiang is a research fellow, and Nemichand B. Jain is director of biopharmaceutics research and development, all at Bristol-Myers Squibb, One Squibb Dr., New Brunswick, NJ 08903, tel. 732.227.5684,

*To whom all correspondence should be addressed.

Submitted: Feb. 23, 2009. Accepted: Apr. 21, 2009.

References

1. I. Ullah et al., Pharm. Technol. 11 (9), 48–54 (1987).

2. C. Chen et al., DrugDev. Ind. Pharm. 16 (3), 379–394 (1990).

3. L.H. Christensen, H.E. Johansen, and T.Schaefer, Drug Dev. Ind. Pharm. 20 (14), 2195–2213 (1994).

4. I. Ullah etal., Pharm. Technol. 33 (11), 62–70 (2009).

5. W. Chen et al., J. Pharm. Innov. 3 (1), 3–14 (2008).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here